The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BBOT | N/A | N/A | N/A | -11% |
| S&P | +18.81% | +68.58% | +11.01% | +33% |
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company is headquartered in South San Francisco, CA.
No news articles found for BridgeBio Oncology Therapeutics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$194.00K | 0.0% |
| Market Cap | $1.00B | 0.0% |
| Market Cap / Employee | $10.89M | 0.0% |
| Employees | 92 | 0.0% |
| Net Income | -$38,797.00K | -2086.4% |
| EBITDA | -$43,214.00K | -19678.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $373.69M | 21910.4% |
| Accounts Receivable | $386.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.24M | 0.0% |
| Short Term Debt | $522.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.83% | -33.6% |
| Return On Invested Capital | 80.47% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$42,307.00K | -48052.7% |
| Operating Free Cash Flow | -$42,234.00K | -47970.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 43.89 | 32.48 | 44.19 | 52.91 | - |
| Price to Book | 1.44 | 2.22 | - | ||
| Price to Tangible Book Value | 1.44 | 2.22 | - | ||
| Enterprise Value to EBITDA | -109.32 | -221.96 | -0.78 | -13.39 | -98.81% |
| Return on Equity | 3.2% | 2.5% | -13.4% | -27.7% | -444.02% |
| Total Debt | $0.00K | $0.00K | $2.89M | $2.77M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
